The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental parkinsonism

dc.contributor.authorGonzález Aparicio, Ramiro José
dc.contributor.authorBlanco Calvo, Eduardo
dc.contributor.authorSerrano, Antonia
dc.contributor.authorPavón, Francisco Javier
dc.contributor.authorParsons, Loren H.
dc.contributor.authorMaldonado, Rafael
dc.contributor.authorRobledo, Patrícia
dc.contributor.authorFernández Espejo, Emilio
dc.contributor.authorRodríguez de Fonseca, Fernando
dc.date.accessioned2015-02-11T14:39:05Z
dc.date.available2015-02-11T14:39:05Z
dc.date.issued2014-03-01
dc.date.updated2015-02-11T14:39:05Z
dc.description.abstractOleoylethanolamide (OEA) is an agonist of the peroxisome proliferator-activated receptor α (PPARα) and has been described to exhibit neuroprotective properties when administered locally in animal models of several neurological disorder models, including stroke and Parkinson's disease. However, there is little information regarding the effectiveness of systemic administration of OEA on Parkinson's disease. In the present study, OEA-mediated neuroprotection has been tested on in vivo and in vitro models of 6-hydroxydopamine (6-OH-DA)-induced degeneration. The in vivo model was based on the intrastriatal infusion of the neurotoxin 6-OH-DA, which generates Parkinsonian symptoms. Rats were treated 2 h before and after the 6-OH-DA treatment with systemic OEA (0.5, 1, and 5 mg/kg). The Parkinsonian symptoms were evaluated at 1 and 4 wk after the development of lesions. The functional status of the nigrostriatal system was studied through tyrosine-hydroxylase (TH) and hemeoxygenase-1 (HO-1, oxidation marker) immunostaining as well as by monitoring the synaptophysin content. In vitro cell cultures were also treated with OEA and 6-OH-DA. As expected, our results revealed 6-OH-DA induced neurotoxicity and behavioural deficits; however, these alterations were less severe in the animals treated with the highest dose of OEA (5 mg/kg). 6-OH-DA administration significantly reduced the striatal TH-immunoreactivity (ir) density, synaptophysin expression, and the number of nigral TH-ir neurons. Moreover, 6-OH-DA enhanced striatal HO-1 content, which was blocked by OEA (5 mg/kg). In vitro, 0.5 and 1 μM of OEA exerted significant neuroprotection on cultured nigral neurons. These effects were abolished after blocking PPARα with the selective antagonist GW6471. In conclusion, systemic OEA protects the nigrostriatal circuit from 6-OH-DA-induced neurotoxicity through a PPARα-dependent mechanism.
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1017/S1461145713001259
dc.identifier.idgrec020234
dc.identifier.issn1461-1457
dc.identifier.urihttp://hdl.handle.net/10459.1/47939
dc.language.isoeng
dc.publisherOxford University Press
dc.publisherCollegium Internationale Neuro-Psychopharmacologicum (CINP)
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1017/S1461145713001259
dc.relation.ispartofInternational Journal of Neuropsychopharmacology, 2014, vol. 17, núm. 3, p. 455-468
dc.rightscc-by-nc (c) Collegium Internationale Neuro-Psychopharmacologicum (CINP) , 2014
dc.rightscc-by-nc (c) Oxford University Press, 2014
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/
dc.subjectDopaminergic neurons
dc.subject6-hydroxydopamine
dc.subjectNeuroprotection
dc.subjectParkinson’s disease
dc.subjectPPARα.
dc.subject.classificationMalaltia de Parkinson
dc.subject.otherParkinson's disease
dc.titleThe systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental parkinsonism
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
020234.pdf
Size:
384.36 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: